ESMO GI 2022

June 29 - July 02, 2022
Barcelona, Spain

ESMO World Congress on Gastrointestinal Cancer

Explore more Hematology-Oncology congress materials

Results(1)

Hematology-Oncology

HERIZON-GEA-01: A Phase 3 Study of Zanidatamab in Combination with Chemotherapy with or without Tislelizumab in First-line Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced/metastatic Gastroesophageal Adenocarcinoma (GEA)

Author(s): Josep Tabernero, Vall d’Hebron Hospital Campus and Institute of Oncology (VHIO), UVic-UCC, IOB-Quiron, Barcelona, Spain

Hematology-Oncology

View Poster

Disclaimer

This AI model is continuing to learn and its responses are based on learned data patterns. It should not replace professional judgment. Please verify the information before use, and feedback is welcome to improve its accuracy.

Please do not include personal or confidential information in your searches. For information on how to report an adverse event or product complaint for a Jazz product, please visit: https://www.jazzpharma.com/medicines/drug-safety/.